A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors
Status:
Not yet recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label study to explore the safety, tolerability, and preliminary
clinical activity of agenT-797, an unmodified, allogeneic iNKT cell therapy, in participants
with relapsed/refractory (r/r) solid tumors, as well as define the recommended phase II dose
(RP2D) in solid tumors. This Phase 1 will also explore the safety, tolerability, and
preliminary clinical activity of agenT-797 in combination with approved immune checkpoint
inhibitors (ICIs), including pembrolizumab and nivolumab, in participants with r/r solid
tumors.